Esteve CDMO, a global CDMO specializing in small-molecule APIs and advanced pharmaceutical intermediates, has expanded its plans for the buildout of a new production unit at its facility in Celrà, Spain.
In parallel to its already-announced plan to expand both production capacity and advanced containment capabilities with a new production unit in Celrà, the company plans to add a further 3,000-square-meter production unit to accommodate additional spray drying equipment and services within purpose-built, high-potency containment suites.
The multi-year investment plans include a GEA Pharma-SD PSD-2 spray dryer, scheduled to be fully operational in the first quarter of 2027, followed by a new PSD-3, expected to come online late 2027. The new building includes space and the necessary infrastructure to include a commercial-scale PSD-4 spray dryer, and a further building project and a second PSD-4 are also planned.
These investments will strengthen ESTEVE CDMO’s ability to handle highly potent compounds safely and efficiently, while reinforcing its technological leadership in amorphous solid dispersion (ASD) solutions.
The company expects to add up to 15 new staff when PSD-2 and PSD-3 operations are fully underway, with PSD-4 operations planned to commence later.
“As our work in Girona progresses, it is important that we remain aligned with the needs of our partners, and adding spray drying capabilities can help solve problems they face with the characteristics of development pipelines, such as stability, poor solubility, potency, and scalability,” said Joan Petit, President at Esteve CDMO. “Proactive investment in our facilities helps us deliver on our vision to be a global CDMO leader in small molecule APIs that is trusted by partners for quality and reliability.”
